Serum anti-SARS-Cov-2 antibody levels (IU/ml) after the 2nd vaccine | ||||||
---|---|---|---|---|---|---|
Controls n = 38 | All patients n = 66 | TNFi n = 34 | RTX n = 27 | Anti-IL6R n = 2 | JAKi n = 3 | p |
625 (405–932) | 94 (42–204) | 123 (43–204) | 4 (0–51) | 64 (61–64) | 40 (18–58) | < 0.0005 |
Serum anti- SARS-CoV-2 antibody levels (IU/ml) after the 3rd vaccine | ||||||
---|---|---|---|---|---|---|
All patients N = 83 | TNFi n = 44 | RTX n = 29 | Anti-IL6R n = 5 | JAKi n = 5 | ||
– | 40 (6.20–153) | 80 (31–204) | 3 (0–27) | 153 (12–196) | 35 (21–562) | 0.03 |